RhumbLine Advisers’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-47,081
| Closed | -$4.57M | – | 2955 |
|
|
2019
Q3 | $4.57M | Sell |
47,081
-2,266
| -5% | -$227K | 0.01% | 1236 |
|
|
2019
Q2 | $5.05M | Buy |
49,347
+6,950
| +16% | +$750K | 0.01% | 1196 |
|
|
2019
Q1 | $4.83M | Buy |
42,397
+25
| +0.1% | +$1.84K | 0.01% | 1201 |
|
|
2018
Q4 | $1.66M | Buy |
42,372
+13,686
| +48% | +$594K | ﹤0.01% | 1764 |
|
|
2018
Q3 | $1.56M | Sell |
28,686
-1,851
| -6% | -$127K | ﹤0.01% | 1784 |
|
|
2018
Q2 | $2.53M | Buy |
30,537
+4,578
| +18% | +$353K | 0.01% | 1548 |
|
|
2018
Q1 | $1.73M | Sell |
25,959
-79
| -0.3% | -$4.56K | ﹤0.01% | 1692 |
|
|
2017
Q4 | $1.34M | Sell |
26,038
-4,352
| -14% | -$313K | ﹤0.01% | 1815 |
|
|
2017
Q3 | $2.71M | Buy |
30,390
+4,112
| +16% | +$312K | 0.01% | 1410 |
|
|
2017
Q2 | $1.57M | Buy |
26,278
+3,626
| +16% | +$203K | ﹤0.01% | 1719 |
|
|
2017
Q1 | $1.21M | Buy |
22,652
+883
| +4% | +$52.4K | ﹤0.01% | 1826 |
|
|
2016
Q4 | $1.09M | Buy |
21,769
+2,145
| +11% | +$115K | ﹤0.01% | 1809 |
|
|
2016
Q3 | $1.18M | Buy |
19,624
+4,108
| +26% | +$237K | ﹤0.01% | 1723 |
|
|
2016
Q2 | $793K | Buy |
15,516
+7,216
| +87% | +$308K | ﹤0.01% | 1929 |
|
|
2016
Q1 | $245K | Buy |
8,300
+595
| +8% | +$18.8K | ﹤0.01% | 2635 |
|
|
2015
Q4 | $349K | Buy |
7,705
+610
| +9% | +$32K | ﹤0.01% | 2478 |
|
|
2015
Q3 | $296K | Buy |
7,095
+220
| +3% | +$11.5K | ﹤0.01% | 2551 |
|
|
2015
Q2 | $414K | Buy |
+6,875
| New | +$455K | ﹤0.01% | 2456 |
|
RhumbLine Advisers's ONCE Position: Q4 2019 in Review
RhumbLine Advisers sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 47,081 shares — an estimated $4.57M sold.
RhumbLine Advisers first reported a position in ONCE in Q2 2015 and held it in 18 quarters. The position peaked at $5.05M in Q2 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- RhumbLine Advisers reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- RhumbLine Advisers sold 47,081 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $4.57M.
- RhumbLine Advisers first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2015 and held it in 18 quarters.
- RhumbLine Advisers's Spark Therapeutics, Inc. Common Stock position peaked at $5.05M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.